利伐沙班治疗老年非瓣膜性心房颤动患者的有效性及安全性分析

目的探讨老年非瓣膜性心房颤动患者采用利伐沙班治疗的有效性及安全性。方法60例老年非瓣膜性心房颤动患者,依据抗凝治疗方法不同分为利伐沙班组和华法林组,各30例。利伐沙班组患者接受利伐沙班抗凝治疗,华法林组患者接受华法林抗凝治疗。比较两组患者的栓塞事件、出血事件、不良反应发生情况。结果利伐沙班组患者的栓塞事件发生率为10.0%(3/30),华法林组患者的栓塞事件发生率为13.3%(4/30),两组比较差异无统计学意义(P>0.05)。利伐沙班组患者的出血事件发生率为3.3%,低于华法林组的20.0%,差异具有统计学意义(P<0.05)。利伐沙班组患者的不良反应发生率为16.7%,低于华法林组的40.0%,差异具有统计学意义(P<0.05)。结论老年非瓣膜性心房颤动患者采用利伐沙班抗凝治疗的有效性及安全性较华法林高,更能有效降低患者的出血事件、不良反应发生率,值得推广。

Analysis of efficacy and safety of rivaroxaban in the treatment of elderly patients with nonvalvular atrial fibrillation

Objective To discuss the efficacy and safety of rivaroxaban in the treatment of elderly patients with nonvalvular atrial fibrillation.Methods A total of 60 elderly patients with nonvalvular atrial fibrillation were divided into rivaroxaban group and warfarin group by different anticoagulant methods,with 30 cases in each group.Rivaroxaban group received rivaroxaban for anticoagulant treatment,and warfarin group received warfarin for anticoagulant treatment.The occurrence of embolism events,bleeding events and adverse reactions were compared between the two groups.Results The incidence of embolism events was 10.0%(3/30)in rivaroxaban group,which was 10.0%(3/30)in warfarin group,and the difference was not statistically significant(P>0.05).The incidence of bleeding events was 3.3%,which was lower than 20.0%in warfarin group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions was 16.7%in rivaroxaban group,which was lower than 40.0%in warfarin group,and the difference was statistically significant(P<0.05).Conclusion The efficacy and safety of rivaroxaban anticoagulation in elderly patients with nonvalvular atrial fibrillation is higher than warfarin,and it can effectively reduce the incidence of bleeding events and adverse reactions.It is worth popularizing.